



BGDO session Program

Scientific Group : BGDO

Day : Friday 2nd, 2024

08:00 – 08:30

Breakfast Symposium MSD

Expert Perspectives on Checkpoint Inhibition in Gastric Adenocarcinoma.
Jeroen Dekervel (UZ Leuven), Vasiliki Siozopoulou (UCL Saint-Luc)

Session 1

Moderators : Leen Mortier (AZ Turnhout), Ivan Borbath (UCL Saint-Luc)

08:30 77 0 01

Impact of [18F] AIF-NOTA-octreotide PET/CT on the therapeutic management of neuroendocrine tumor patients.

H. LEUPE (1), E. PAUWELS (1), T. VANDAMME (2), W. LYBAERT (3), B. VAN DEN BROECK (4), C. VERSLYPE (5), J. JAEKERS (6), F. VAN HERPE (5), J. HOFLAND (7), F. CLEEREN (8), A. BROUWERS (9), G. BORMANS (8), M. KOOLE (10), E. VAN CUTSEM (5), K. GEBOES (11), A. LAENEN (12), J. DEKERVEL (5), S. STROOBANTS (13), C. DEROOSE (1) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Nuclear Medicine, [2] Universiteit Antwerpen / Antwerp University Hospital, WILRIJK (Antwerpen), Belgium, Oncology, [3] NETwerk Antwerpen-Waasland CoE, Edegem, Belgium, Oncology, [4] Ghent University Hospital, Ghent, Belgium, Nuclear Medicine, [5] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Digestive Oncology, [6] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Visceral Surgery, [7] Erasmus MC, University Medical Center Rotterdam, Netherlands (the), Department of Internal Medicine, Section of Endocrinology, [8] KUL - University of Leuven, Leuven, Belgium, Radiopharmaceutical Research, [9] University Medical Center Groningen, Groningen, Netherlands (the), Nuclear Medicine and Molecular Imaging, [10] KUL - University of Leuven, Leuven, Belgium, Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, [11] Ghent University Hospital, Ghent, Belgium, Digestive Oncology, [12] KUL - University of Leuven, Leuven, Belgium, Biostatistics and Statistical Bioinformatics Center, [13] University hospital of Antwerp, Edegem, Belgium, Nuclear Medicine

08:40 65 O 02

Sequential Everolimus and Sunitinib treatment in metastatic pancreatic neuroendocrine neoplasms after failure of previous treatments.

O. ISLAM (1), G. VAN DE VYVER (2), C. VERSLYPE (3), I. BORBATH (4), J. DECAESTECKER (5), T. BOTELBERGE (6), K. GEBOES (7), P. CUYLE (8), M. CLAUSSE (9), C. GEORGE (10), M. POLUS (11), J. COCHE (12), J. VAN LAETHEM (13), W. DEMEY (14), A. BOLS (15), G. DEMOLIN (16), L. D'HONDT (17), M. SIMOENS (18), S. CHHAJLANI (19), I. VAN DER MASSEN (20), L. MARIËN (20), L. WILLEM (21), M. PEETERS (22), T. VANDAMME (22) / [1] NETwerk Antwerpen-Waasland CoE, Edegem, Belgium, Medical oncology, [2] NETwerk Antwerpen-Waasland CoE, Edegem, Belgium, Gastro-Enterology, [3] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Digestive Oncology, [4] UCL Saint Luc, Brussels, Belgium, Digestive Oncology, [5] AZ Delta, Roeselare, Belgium, Digestive Oncology, [6] NETwerk, GZA , Antwerpen, Belgium, Digestive Oncology, [7] University Hospital Ghent (UZ Gent), Gent, Belgium, Digestive Oncology, [8] Imelda Hospital, Bonheiden, Belgium, Digestive Oncology, [9] Clinique Saint-luc Bouge, Namur, Belgium, Medical oncology, [10] AZ Groeninge, Kortrijk, Belgium, Digestive Oncology, [11] CHR Verviers, Verviers, Belgium, Digestive Oncology, [12] Clinique Saint-Pierre, Ottignies, Belgium, Digestive Oncology, [13] Hopital Erasme, ULB, Belgium, Digestive Oncology, [14] NETwerk, AZ KLINA, Brasschaat, Belgium, Digestive Oncology, [15] AZ Sint-Jan Brugge-Oostende, Brugge, Belgium, Medical oncology, [16] CHC, Liège, Belgium, Digestive Oncology, [17] CHU-UCL-Namur site Godinne, Yvoir, Belgium, Medical oncology, [18] NETwerk, ZNA, Antwerpen, Belgium, Digestive Oncology, [19] UZA - NETwerk, Edegem, Belgium, Medical oncology, [20] UZA - NETwerk, Edegem, Belgium, NETwerk, [21] NETwerk, VITAZ Sint-Niklaas/UZA, Edegem, Belgium, Medical oncology, [22] UZA - NETwerk, Edegem, Belgium, Digestive Oncology

08:50 217 O 03

Quali-NET: a prospective quality of life study on patient-reported outcomes in neuroendocrine neoplasms.

O. ISLAM (1), L. DEPAUW (2), I. VAN DER MASSEN (3), L. MARIËN (3), S. CHHAJLANI (2), C. DE WEERDT (3), M. SIMOENS (4), D. GALDERMANS (5), W. DEMEY (6), T. BOTELBERGE (7), M. ULENAERS (8), T. RONDOU (8), W. LYBAERT (9), M. PEETERS (10), T. VANDAMME (10) / [1] UZA, Universitair Ziekenhuis Antwerpen, Edegem, Belgium, Oncology, [2] UZA - NETwerk, Edegem, Belgium, Medical oncology, [3] UZA - NETwerk, Edegem, Belgium, NETwerk, [4] NETwerk, ZNA, Antwerpen, Belgium, Digestive Oncology, [5] NETwerk, ZNA, Antwerpen, Belgium, Thorax Oncology, [6] NETwerk, AZ KLINA, Brasschaat, Belgium, Digestive

Oncology, [7] NETwerk, GZA , Antwerpen, Belgium, Digestive Oncology, [8] NETwerk, AZ Rivierenland Rumst/Bornem, Rumst, Belgium, Digestive Oncology, [9] NETwerk, VITAZ/UZA, Edegem, Belgium, Medical oncology, [10] UZA - NETwerk, Edegem, Belgium, Digestive Oncology

09:00 Discussant abstracts 77, 65 and 217 on NET:

Ivan Borbath (UCL Saint-Luc) □ 15 min for discussant and 5 min for Q/A

09:20 Invited Lecture: HER2-directed therapies in GI malignancies: State of the art and future developments (30min lecture and 10min discussion)

Eric Van Cutsem (UZ Leuven)

10:00-10:30 COFFEE BREAK

Session 2

Moderators : Veerle Casneuf (OLV Aalst), Karen Geboes (UZ Gent)

10:30 35 O 04 The relation between overall survival and recurrence-free survival identifies different metastatic behaviors in patients operated for colorectal liver metastases.

B. BEN MHAMMED (1), A. BOHLOK (1), M. MOREAU (2), V. LUCIDI (1), J. VAN LAETHEM (3), A. HENDLISZ (3), V. DONCKIER (1) / [1] Hopitaux Universitaires de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Belgium, Abdominal surgery, [2] Hopitaux Universitaires de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Belgium, Statistics, [3] Hopitaux Universitaires de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Belgium, Digestive oncology

10:40 45 O 05 INTERNATIONAL REAL-WORLD STUDY OF TOTAL NEOADJUVANT THERAPY (TNT) FOR LOCALLY ADVANCED RECTAL CANCER (LARC).

A. AUDISIO (1), . LEUVEN RECTAL CANCER GROUP (2), A. VANDEN BULCKE (3), M. VAN DEN EYNDE (4), A. DERMINE (5), F. PULEO (6), M. DIAZ (7), Q. GILLIAUX (8), A. DELEPORTE (9), K. GEBOES (10), P. MARTINIVE (11), T. VANDAMME (12), A. HENDLISZ (13), J. VAN LAETHEM (13), F. SCLAFANI (1) / [1] Hôpital Universitaire de Bruxelles, Bruxelles, Belgium, Department of Gastrointestinal Oncology, [2] University Hospitals Gasthuisberg, Leuven and KU Leuven, Leuven, Belgium, Digestive Oncology, Dept of Oncology, KU Leuven, [3] AZ Groeninge, Kortrijk, Belgium, Department of Gastroenterology, [4] Cliniques universitaires Saint-Luc, Brussels, Belgium, Service d'oncologie médicale et de gastro-entérologie, [5] Centre Hospitalier de Jolimont-Lobbès., La Louvière, Belgium, Department of Gastrointestinal Oncology, [6] Chirec delta, Auderghem, Belgium, Department of Gastroenterology, [7] CHU Ambroise Paré MONS, Mons, Belgium, Department of Gastroenterology, [8] Université catholique de Louvain, CHU UCL

Namur, Yvoir, Belgium, Department of Gastrointestinal Oncology, [9] CHU Saint-Pierre, Brussels, Belgium, Department of Gastrointestinal Oncology, [10] Universitair ziekenhuis Gent, Belgium, Department of Gastrointestinal Oncology, [11] Institut Jules Bordet, Brussels, Belgium, Department of Radiotherapy, [12] UZA, Universitair Ziekenhuis Antwerpen, Edegem, Belgium, Department of Gastrointestinal Oncology, [13] Hôpital Universitaire de Bruxelles, Bruxelles, Belgium, Department of Gastrointestinal Oncology

10:50 Discussant abstracts on CRC:

Amy De Haar (UZ Brussel)/Holleman □ 10 min for discussant and 5 min for Q/A

11:05 7 O 06 **Immuno-molecular modulation in pancreatic cancer following isotoxic high-dose stereotactic body radiotherapy (iHD-SBRT).**
C. BOUCHART (1), O. AZURMENDI SENAR (2), J. NAVEZ (3), L. VERSET (4), A. BOISSON (5), M. HEIN (6), N. D'HAENE (7), D. VAN GESTEL (8), L. MORETTI (8), P. DEMETTER (9), J. BACHET (10), K. WILLARD-GALLO (5), R. NICOLLE (11), T. ARSENIJEVIC (2), J. VAN LAETHEM (12) / [1] Institut Jules Bordet, Brussels, Belgium, Radiotherapy-Oncology, [2] ULB, Brussels, Belgium, Laboratory of Experimental Gastroenterology, [3] Erasme University Hospital – Université Libre de Bruxelles (ULB), Bruxelles, Belgium, Hepatobiliary-pancreatic surgery, [4] Institut Jules Bordet, Brussels, Belgium, Pathology, [5] Institut Jules Bordet, Brussels, Belgium, Laboratory of Molecular Immunology, [6] ULB, Brussels, Belgium, Faculty of Medicine, [7] Erasme University Hospital – Université Libre de Bruxelles (ULB), Bruxelles, Belgium, Pathology, [8] Institut Jules Bordet, Brussels, Belgium, Radiation-Oncology, [9] ULB, Brussels, Belgium, Pathology, [10] Hopital de La Pitié Salpêtrière, Paris, France, Gastroenterology, [11] INSERM, France, Hepatogastroenterology, [12] Erasme University Hospital - Université Libre de Bruxelles (ULB), Bruxelles, Belgium, Digestive Oncology

11:15 214 O 07 **A retrospective outcome analysis of KRAS wild type and KRAS mutated pancreatic adenocarcinoma including targeted drug therapies**
L. MERTENS (1), F. PEETERS (2), J. JAEKERS (3), H. TOPAL (3), B. TOPAL (3), I. VANDEN BEMPT (4), G. DE HERTOIGH (5), T. ROSKAMS (5), X. SAGAERT (5), C. VERSLYPE (6), G. RASSCHAERT (6), F. VAN HERPE (6), J. DEKERVEL (6) / [1] KUL - University of Leuven, Leuven, Belgium, Faculteit Geneeskunde, [2] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Internal Medicine, [3] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Abdominal Surgery, [4] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Center for Human Genetics, [5] University Hospitals Leuven (UZLeuven), Leuven, Belgium,

Pathology, [6] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Digestive Oncology

11:25 Discussant abstracts on pancreas:
Timon Vandamme (UZ Antwerpen) 10 min for discussant and 5 min for Q/A

11:40 **Brohée Lecture: "Revisiting pancreatic cancer treatment."**
(30 min lecture and 10 min discussion)
Jean Luc Van Laethem (HUB Bordet Erasme - ULB)

12:15 BGDO trophy (Best abstract)
Communications,
Chairman conclusions

12:30 End of the meeting

12:30 – 13:15 ***Satellite Symposium ASTRAZENECA***

The use of immunotherapies in complex patient cases in HCC & BTC.
A. Demols (ULB Erasme, Bruxelles), T. Vandamme (UZ Antwerpen)

e-POSTERS

- 6 O 08 The radiological morphology of mesopancreas, a new variable to predict a positive vascular margin after pancreatoduodenectomy for pancreatic ductal adenocarcinoma?
J. NAVEZ (1), M. PEZZULO (2), C. BOUCHART (3), T. ARSENIJEVIC (4), P. DEMETTER (4), J. CLOSSET (1), J. DEVIERE (5), L. VERSET (6), M. BALI (2), J. VAN LAETHEM (7) / [1] Hôpital Universitaire de Bruxelles, Bruxelles, Belgium, Abdominal Surgery and Transplantation, [2] Hôpital Universitaire de Bruxelles, Bruxelles, Belgium, Radiology, [3] Hôpital Universitaire de Bruxelles, Bruxelles, Belgium, Radiotherapy, [4] Université Libre de Bruxelles, Bruxelles, Belgium, Laboratoire de Gastroentérologie Expérimentale, [5] Hôpital Universitaire de Bruxelles, Bruxelles, Belgium, Gastroenterology, [6] Hôpital Universitaire de Bruxelles, Bruxelles, Belgium, Pathology, [7] Hôpital Universitaire de Bruxelles, Bruxelles, Belgium, Digestive Oncology
- 19 O 09 Correlation of the volume of the liver graft measured with CT & MRI, compared with the intraoperative data.
E. DANSE (1), D. LACOMBLEZ (2), L. COUBEAU (3), O. CICCARELLI (3), E. BONACCORSI (3), C. DE MAGNEE (3), R. REDING (3), N. MICHOUX (2) / [1] Cliniques universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium, Radiology, [2] Cliniques universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium, Imaging, [3] Cliniques universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium, Transplantation and abdominal Surgery
- 44 O 10 Prognostic value of circulating cytokines in chemorefractory colorectal cancer.
I. ASSAF (1), D. FIMERELI (2), G. ANTHOINE (3), R. FAZIO (4), V. DAPRA (4),

A. AUDISIO (4), T. AKIN TELLI (4), M. VAN HOOREN (4), R. SAUDE CONDE (4), G. BREGNI (4), A. HENDLISZ (1), F. SCLAFANI (1) / [1] Institut Jules Bordet, Brussels, Belgium, Department of Digestive Oncology, Institut Jules Bordet, The Brussels University Hospital, Brussels, Belgium, [2] Institut Jules Bordet, Brussels, Belgium, Breast Cancer Translational Laboratory, Bordet Cancer Research Laboratory, [3] Institut Jules Bordet, Brussels, Belgium, GI Cancer Laboratory, Bordet Cancer Research Laboratory, Institut Jules Bordet, [4] Institut Jules Bordet, Brussels, Belgium, Department of Digestive Oncology, Institut Jules Bordet

- 114 O 11 Clinical outcomes after surgery for progressive lesions in oligoprogressive metastatic MMR-deficient gastro-intestinal cancer: a case series.
P. PERREMANS (1) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Gastro-enterologie
- 141 O 12 Selective internal radiation therapy for neuroendocrine liver metastases: efficacy, safety and prognostic factors. A retrospective single institution study.
D. BRIOL (1), A. CERATTI (1), L. ANNET (2), C. DRAGEAN (2), E. DANSE (2), P. TREFOIS (2), R. LHOMMEL (3), P. GOFFETTE (2), M. VAN DEN EYNDE (1), A. DE CUYPER (1), I. BORBATH (4) / [1] Cliniques universitaires Saint-Luc, Brussels, Belgium, Oncology, [2] Cliniques universitaires Saint-Luc, Brussels, Belgium, Radiology, [3] Cliniques universitaires Saint-Luc, Brussels, Belgium, Nuclear Medicine, [4] Cliniques universitaires Saint-Luc, Brussels, Belgium, Gastroenterology
- 172 O 13 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: a case exposing current unmet needs.
J. VAN DURME (1), A. JANS (1), Z. HU (1), A. PEDDLE (1), A. BILLIET (2), F. VAN HERPE (2), X. SAGAERT (3), A. WOLTHUIS (4), S. TEJPAR (5), G. RASSCHAERT (5) / [1] KUL - University of Leuven, Leuven, Belgium, Laboratory of Digestive Oncology, [2] University Hospitals Leuven (UZ Leuven), Leuven, Belgium, Gastroenterology, [3] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Pathology, [4] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Abdominal Surgery, [5] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Gastroenterology & Laboratory of Digestive Oncology
- 180 O 14 Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumor pAtients (SAUNA trial) — study protocol for a bi-national, multi-center, open-label, randomized, pragmatic.
S. CHHAJLANI (1), J. KUIPER (2), I. BORBATH (3), W. DERCKSEN (4), C. DEROOSE (5), S. HEEMSKERK (6), S. POLINDER (6), E. ROELANT (7), I. VERHAEGEN (7), I. VAN DER MASSEN (1), A. WALENKAMP (8), W. DE HERDER (2), M. PEETERS (1), J. HOFLAND (2), T. VANDAMME (1), -. SAUNA INVESTIGATORS (9), -. DUTCH BELGIAN NEUROENDOCRINE TUMOR SOCIETY

(10) / [1] UZA (Universitair Ziekenhuis Antwerpen) - NETwerk, Edegem, Belgium, Medical Oncology, [2] Erasmus MC, University Medical Center Rotterdam, , Netherlands (the), Internal Medicine, [3] UCL Saint Luc, Brussels, Belgium, Digestive Oncology, [4] Máxima MC, Eindhoven, Netherlands (the), Internal Medicine, [5] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Nuclear Medicine, [6] Erasmus MC, University Medical Center Rotterdam, Netherlands (the), Public Health, [7] UZA, Universitair Ziekenhuis Antwerpen, Edegem, Belgium, Clinical Trial Center, [8] University Medical Center Groningen, Groningen, Netherlands (the), Medical Oncology, [9] UZA (Universitair Ziekenhuis Antwerpen) - NETwerk, Edegem, Belgium, NA, [10] DBENTS, Belgium, Netherlands (the), NA

- 182 O 15 Apport de l'endoscopie dans le diagnostic des cancers gastriques en République Démocratique du Congo. A propos 3068 endoscopies digestives hautes à l'Hôpital Général de Référence de Panzi/Bukavu.
M. JOSUE (1), C. CHASSINGA BAHARANYI (2), C. MUGISHO MASTAKI (1), G. BYABENE (3), M. VAN GOSSUM (4) / [1] Panzi Hospital DR Congo, Bukavu, Congo (the Democratic Republic of the), gastroenterology, [2] Panzi Hospital DR Congo, Bukavu, Congo (the Democratic Republic of the), anatomopathology, [3] Panzi Hospital DR Congo, Bukavu, Congo (the Democratic Republic of the), surgery, [4] CHU Saint-Pierre, Brussels, Belgium, gastroenterology
- 212 O 16 A novel deletion mutation in GAPPS: Insights from a comprehensive family-based case analysis.
C. VAN LAEKEN (1), J. CALLENS (2), A. VAN GOETHEM (3) / [1] KUL - University of Leuven, Leuven, Belgium, Department of Gastroenterology, [2] AZ Klina, Brasschaat, Belgium, Department of Gastroenterology, [3] AZ Klina, Brasschaat, Belgium, Department of Oncology
- 226 O 17 Prognosis after curative resection of nonmetastatic pancreatic neuroendocrine tumors: a retrospective tertiary center study.
T. HENDRICKX (1), J. VANCANNEYT (1), J. DEKERVEL (1), G. RASSCHAERT (1), F. VAN HERPE (1), J. JAEKERS (2), H. TOPAL (2), B. TOPAL (2), C. DEROOSE (3), V. VANDECAVEYE (4), C. VERSLYPE (1) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Gastro-enterology and hepatology, [2] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Abdominal surgery, [3] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Nuclear Medicine, [4] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Radiology